SCHEMBL5692467

SCHEMBL5692467

CN(C)C(=O)COc1ccc(C=Cc2n[nH]c3ccccc23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.49
CHEK1 O14757 7/20 0.49
FGFR1 P11362 5/20 0.49
LCK P06239 2/20 0.49
CDK4 P11802 2/20 0.49
AURKA O14965 2/20 0.49
BMPR1B O00238 1/20 0.49
PLK4 O00444 1/20 0.49
STK25 O00506 1/20 0.49
CIT O14578 1/20 0.49
RIOK3 O14730 1/20 0.49
IKBKB O14920 1/20 0.49
GAK O14976 1/20 0.49
DCLK1 O15075 1/20 0.49
CHUK O15111 1/20 0.49
MUSK O15146 1/20 0.49
EPHB6 O15197 1/20 0.49
PDPK1 O15530 1/20 0.49
MAP3K13 O43283 1/20 0.49
DAPK3 O43293 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5692464 1.00 KDR (0.49) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5692347 0.86 KDR (0.53) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5692344 0.86 KDR (0.53) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5692573 0.84 KDR (0.49) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5692569 0.84 KDR (0.49) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5692245 0.84 CHEK1 (0.43) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5692242 0.84 CHEK1 (0.43) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5692301 0.83 CHEK1 (0.51) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5692299 0.83 CHEK1 (0.51) KDRCHEK1FGFR1LCKCDK4
Hydrochloric Acid SCHEMBL5692606 0.81 KDR (0.49) KDRCHEK1FGFR1LCKCDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060281789-A1 Protein kinase inhibitors KYOWA HAKKO KOGYO CO., LTD (JP) 2006-12-14 US disclosed
EP-1650194-A1 PROTEIN KINASE INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281789-A1 Protein kinase inhibitors MAP3K20, MAP3K1, MAP3K19 KDR 1545/4885CHEK1 247/4885FGFR1 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.